{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105027","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.367597+00:00","generated_at":"2026-05-17T17:05:30.950457+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RxSight Q2 revenue $33.6M (-4% YoY); net loss $(11.8)M; reaffirms FY2025 guidance","bullets":["Total revenue $33.6M, down 4% from $34.9M in Q2 2024; LAL units up 13%, LDD units down 49%.","Net loss $(11.8)M ($(0.29)/share) vs $(6.1)M loss a year ago; adjusted net loss $(3.2)M.","Installed LDD base grew 34% to 1,084 units; FDA approved expanded LAL diopter range to -2.0 to +3.0.","Launched Light Adjustable Lens system in South Korea and Singapore; commercial team realigned.","Reaffirmed FY2025 revenue guidance $120M-$130M, gross margin 72%-74%, opex $145M-$155M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105027","json":"https://secwatch.observer/filing/0000950170-25-105027.json","markdown":"https://secwatch.observer/filing/0000950170-25-105027.md","text":"https://secwatch.observer/filing/0000950170-25-105027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/0000950170-25-105027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017025105027/rxst-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:05:30.950457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}